Review



ovalbumin-specific t cell receptor transgenic (ot-ii) mice  (Jackson Laboratory)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Jackson Laboratory ovalbumin-specific t cell receptor transgenic (ot-ii) mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ovalbumin Specific T Cell Receptor Transgenic (Ot Ii) Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ovalbumin-specific t cell receptor transgenic (ot-ii) mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ovalbumin-specific t cell receptor transgenic (ot-ii) mice - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection"

    Article Title: Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI172218

    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 transgenic mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Figure Legend Snippet: ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 transgenic mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).

    Techniques Used: Transgenic Assay, Transplantation Assay, Staining, Enzyme-linked Immunospot, MANN-WHITNEY, Flow Cytometry, In Vitro, Suppression Assay, Activity Assay, Comparison



    Similar Products

    ova-specific tcr-transgenic ot-ii mice c57bl/6-tg(tcratcrb)425cbn/crl  (Charles River Laboratories)
    90
    Charles River Laboratories ova-specific tcr-transgenic ot-ii mice c57bl/6-tg(tcratcrb)425cbn/crl
    Ova Specific Tcr Transgenic Ot Ii Mice C57bl/6 Tg(Tcratcrb)425cbn/Crl, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ova-specific tcr-transgenic ot-ii mice c57bl/6-tg(tcratcrb)425cbn/crl/product/Charles River Laboratories
    Average 90 stars, based on 1 article reviews
    ova-specific tcr-transgenic ot-ii mice c57bl/6-tg(tcratcrb)425cbn/crl - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ovalbumin-specific t cell receptor transgenic (ot-ii) mice  (Jackson Laboratory)
    90
    Jackson Laboratory ovalbumin-specific t cell receptor transgenic (ot-ii) mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ovalbumin Specific T Cell Receptor Transgenic (Ot Ii) Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ovalbumin-specific t cell receptor transgenic (ot-ii) mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ovalbumin-specific t cell receptor transgenic (ot-ii) mice - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    t cell receptor transgenic mice specific for h–2ia b ova 323–339 (ot-ii)  (Cyagen Biosciences)
    90
    Cyagen Biosciences t cell receptor transgenic mice specific for h–2ia b ova 323–339 (ot-ii)
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    T Cell Receptor Transgenic Mice Specific For H–2ia B Ova 323–339 (Ot Ii), supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t cell receptor transgenic mice specific for h–2ia b ova 323–339 (ot-ii)/product/Cyagen Biosciences
    Average 90 stars, based on 1 article reviews
    t cell receptor transgenic mice specific for h–2ia b ova 323–339 (ot-ii) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    t cell receptor transgenic mice specific for h–2iab ova323–339 (ot-ii)  (Cyagen Biosciences)
    90
    Cyagen Biosciences t cell receptor transgenic mice specific for h–2iab ova323–339 (ot-ii)
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    T Cell Receptor Transgenic Mice Specific For H–2iab Ova323–339 (Ot Ii), supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t cell receptor transgenic mice specific for h–2iab ova323–339 (ot-ii)/product/Cyagen Biosciences
    Average 90 stars, based on 1 article reviews
    t cell receptor transgenic mice specific for h–2iab ova323–339 (ot-ii) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot-ii tcr transgenic mice  (Jackson Laboratory)
    90
    Jackson Laboratory ot-ii tcr transgenic mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Tcr Transgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot-ii tcr transgenic mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ot-ii tcr transgenic mice - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot- ii tcr transgenic female mice  (Cyagen Biosciences)
    90
    Cyagen Biosciences ot- ii tcr transgenic female mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Tcr Transgenic Female Mice, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot- ii tcr transgenic female mice/product/Cyagen Biosciences
    Average 90 stars, based on 1 article reviews
    ot- ii tcr transgenic female mice - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot-ii transgenic mice c57bl/6-tg (tcratcrb)425cbn  (Jackson Laboratory)
    90
    Jackson Laboratory ot-ii transgenic mice c57bl/6-tg (tcratcrb)425cbn
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Transgenic Mice C57bl/6 Tg (Tcratcrb)425cbn, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot-ii transgenic mice c57bl/6-tg (tcratcrb)425cbn/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ot-ii transgenic mice c57bl/6-tg (tcratcrb)425cbn - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot-ii transgenic mice b6.cg-tg(tcratcrb)425cbn/j  (Jackson Laboratory)
    90
    Jackson Laboratory ot-ii transgenic mice b6.cg-tg(tcratcrb)425cbn/j
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Transgenic Mice B6.Cg Tg(Tcratcrb)425cbn/J, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot-ii transgenic mice b6.cg-tg(tcratcrb)425cbn/j/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ot-ii transgenic mice b6.cg-tg(tcratcrb)425cbn/j - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot-ii transgenic mice  (Taconic Biosciences)
    90
    Taconic Biosciences ot-ii transgenic mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Transgenic Mice, supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot-ii transgenic mice/product/Taconic Biosciences
    Average 90 stars, based on 1 article reviews
    ot-ii transgenic mice - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    ot-ii tcr-transgenic mice  (Jackson Laboratory)
    90
    Jackson Laboratory ot-ii tcr-transgenic mice
    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 <t>transgenic</t> mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).
    Ot Ii Tcr Transgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ot-ii tcr-transgenic mice/product/Jackson Laboratory
    Average 90 stars, based on 1 article reviews
    ot-ii tcr-transgenic mice - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 transgenic mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).

    Journal: The Journal of Clinical Investigation

    Article Title: Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection

    doi: 10.1172/JCI172218

    Figure Lengend Snippet: ( A – F ) Single MHC class II mismatched B6.C-H-2 bm12 donor hearts were transplanted into NRP2 transgenic mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. ( A ) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2 bm12 heart allografts into WT, NRP2 –/– , or ΔNRP2-CD4-KO recipients. ( B ) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. ( C ) CD4 + T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). ( D and E ) Allograft survival after transplantation of B6.C-H-2 bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2 lox/lox recipients. ( E ) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. ( F ) Kaplan-Meier survival curves after transplantation of B6.C-H-2 bm12 cardiac allografts into C57BL/6 NRP2 lox/lox , ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. ( G – I ) C57BL/6 NRP2 lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. ( G and H ) A representative Treg suppression assay showing proliferation of NRP2 WT ( G ) or KO ( H ) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). ( I ) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2 lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).

    Article Snippet: Ovalbumin-specific T cell receptor transgenic (OT-II) mice were gifted by Hans Oettgen (Boston Children’s Hospital, Boston, MA) and originally purchased from the Jackson Laboratory.

    Techniques: Transgenic Assay, Transplantation Assay, Staining, Enzyme-linked Immunospot, MANN-WHITNEY, Flow Cytometry, In Vitro, Suppression Assay, Activity Assay, Comparison